Objective: In Canada, treatment of children and adolescents with antipsychotics is almost always off label. A single atypical agent, aripiprazole, only recently received regulatory authorization for use in the group aged 15 to 17 years. This regulatory approval was restricted to treatment of schizophrenia. The objective of this review was to summarize pharmacoepidemiologic reports examining the frequency of use of these medications.
Abbreviations

Clinical Implications
• Canadian pharmacoepidemiologic data on the frequency of use of SGAs in children and adolescents are scarce.
• Available evidence suggests that use of these medications in Canada is lower than in the United States, higher than what has been reported in Italy, and comparable to that of France and the Netherlands.
Limitations
• International studies are not necessarily comparable owing to methodological differences.
• While various international studies have reported divergent estimates, it is impossible to definitively state what actually are the optimal frequencies.
A lthough the classification of antipsychotics into FGAs and SGAs is somewhat arbitrary, 1 the term SGAs continues to be used to describe a group of antipsychotics believed to cause fewer extrapyramidal symptoms and to have a lower risk of tardive dyskinesia than FGAs. Their introduction has led to major changes in the patterns of use of antipsychotics. SGAs have become not only generally preferred agents for the treatment of psychotic disorders but also increasingly used for a broad set of therapeutic indications, sometimes without regulatory approval. Until recently, there were no approved indications for antipsychotics in children and youth in Canada. Psychotic disorders, mood disorders, symptoms associated with pervasive developmental disorders, CDs, ADHD, and Tourette syndrome are all targets of off-label treatment. The adverse effects of SGAs include metabolic changes and weight gain, which can have lifelong implications for children and adolescents treated with these medications. The objective of this review was to summarize published descriptions of the evolving pharmacoepidemiology of these medications.
Methods
The literature search adopted several strategies. First, MEDLINE was searched, using OVID and adopting a search strategy described below. Next, one reviewer reviewed the abstracts of papers uncovered in this search for relevance and reviewed the text of papers deemed to be relevant to the goals of the review. Additional papers were identified because they were cited in the identified sources or in widely cited articles. 2, 3 The MEDLINE search used 3 sets of key words linked by "or" and these searches were later combined using "and". The first set of key words included "antipsychotic. mp. or exp Antipsychotic Agents/" or "risperidone.mp. or exp Risperidone/" or "aripiprazole.mp" or "ziprasidone. mp" or "olanzapine.mp" or "quetiapline.mp" or "clozapine. mp or exp Clozapine/" or paliperidone.mp". The second set included "children.mp. or exp Child/" or "exp Adolescent Medicine/ or exp Adolescent Psychiatry/ or exp Adolescent/ or exp Adolescent Health Services/ or adolescent.mp". Finally, the third set included "exp Epidemiology/ or epidemiology.mp" or "pharmacoepidemiology.mp. or exp Pharmacoepidemiology/". Review of the abstracts from these papers determined that 5 were pharmacoepidemiologic studies potentially relevant to the review. These studies were from Italy, 4-6 the United Kingdom, 7 and the United States. 8 The US study was found to be a case series concerned with phenothiazine and butyrophenone poisonings. A large number of additional pharmacoepidemiologic studies from the United States and other countries were identified through the scanning of reference lists, including 2 reviews identified in the search. One pharmacoepidemiologic study 9 reported data only for the group aged 18 years and older and was therefore excluded from the review. Among the remaining papers, 6 were not eligible because they did not use populationbased samples, 2 papers were concerned with neurobiology and (or) pathophysiology, and 7 were pharmacovigilance reports. [10] [11] [12] [13] [14] [15] [16] The remaining 26 papers were concerned with topics not relevant to the review. Finally, one additional paper that was published after completion of the review was included because it reported Canadian data. 17
Results
European Estimates
While 3 pharmacoepidemiologic studies of antipsychotic use in Italy were uncovered, age-specific rates were not reported by 2 of these studies. 4, 5 A study by Trifiró et al 6 focused on general practice registrants aged 15 to 80-plus years and reported counts of those taking SGAs in the group aged 15 to 29 years. These counts increased 5-fold between 1999 and 2002 6 ; however, in the population studied, typical antipsychotics were used more frequently than atypical antipsychotics in each of the 4 years. This provided a stark contrast with the situation in some other countries, as described below. Clavenna et al 18 used a multiregional drug use monitoring system capable of capturing nationally reimbursed prescriptions (including risperidone and olanzapine) within defined populations and thereby allowing estimation of population rates and trends between 1998 and 2004 in the group aged 0 to 17 years. The study did not identify a trend toward increasing rates of antipsychotic use, with the 2004 estimate being 0.68 per 1000 population.
The highest frequency was observed in boys aged 14 to 17 years.
A French study 19 reporting the frequency of psychotropic claims to a large health organization examined a representative random sample of 6534 children and adolescents aged 17 years and younger in 2003. Only 9 claims for antipsychotics were identified. 19 More than 4300 members of the sample were aged 10 years and younger, but none of these subjects had a medication claim for an antipsychotic. However, this study 19 was not population based. A larger study, 20 using linkage of administrative data for 3 national agencies together covering 96.6% of the French population, reported a prevalence estimate for antipsychotic use in 2004 of 3.4 per 1000 (4.2 in boys and 2.6 in girls) for the population aged 18 years and younger. The estimates increased with age, peaking in the category aged 15 to 18 years at 6.8 per 1000. 20 A study conducted in the Netherlands 21 used a population database linked to pharmacy records to estimate population rates for a geographical area as well as rates of change over time of antipsychotic use. The prevalence of antipsychotic use for youth aged 19 years and younger increased progressively from 3.0 to 6.8 per 1000 between 1997 to 2005, about 10 times higher than the 2004 rate reported by Clavenna et al 18 in Italy, but nearly identical to population-based French estimates. 20 In 1997, the rates of SGA prescription were lower than those for FGAs (0.6 and 2.5 per 1000, respectively), a pattern that had reversed by 2005 (5.1 and 2.1 per 1000, respectively). Duration of antipsychotic use doubled over the same interval to a median duration of 0.7 years in females and 2.7 years in males. Both an increased incidence and longer duration of use are expected to increase prevalence in the population. Clark 7 examined new prescriptions in all 21 Child and Adolescent Mental Health Services (commonly referred to as CAMHS) within the Greater Manchester and Lancashire zones of the North West region of England. A total of 845 new prescriptions were written within two 6-month periods between 1999 and 2001. At that time, both SGAs and FGAs were prescribed at about equal frequencies (7.1% and 7.3% of prescriptions, respectively). The data could not be used to calculate a population rate. However, population rates for GP prescriptions of antipsychotics in the United Kingdom were reported by Rani et al. 22 During the interval examined, between 1992 and 2005, overall prescriptions nearly doubled, from 0.39 to 0.77 users per 1000 patient-years-the increase was due to increasing use of SGAs, as prescriptions for FGAs declined during the interval. These estimates resemble those of Clavenna et al, 18 which were also based on a registry of GP prescribing. The most commonly prescribed SGA was risperidone at 73%. Consistent with other studies, 21, 23 there was evidence that longer durations of use of the medications was contributing to the increased prevalence of use, as the incidence of new use did not increase.
US Studies
Constantine et al 24 used Florida Medicaid claims (fee-forservice pharmacy, physician services, and institutional claims) and Medicaid identification numbers to identify a cohort of children aged 5 years and younger who were enrolled in the Florida Medicaid program and who initiated an antipsychotic treatment episode at any time between July 1, 2003, and June 30, 2004 . Risperidone was the most frequently used antipsychotic (69.5%) and FGAs were almost never used in this population. Children treated with antipsychotics were more likely to be male, less likely to be black or Hispanic, and most commonly had ADHD, DBDs, or pervasive developmental disorders. Olfson et al 25 A broader age range (19 years and younger) was examined by Patel et al 3 using Texas Medicaid data between 1996 and 2000. In 1996, the rate of FGA use (per 1000 enrollees) was 4.94, compared with 2.69 for SGAs. By 2000, these rates were 3.89 and 15.98, respectively. The greatest relative increase was seen in children aged 5 to 9 years (where the rate of use of SGAs increased by 609% during this interval). However, the highest absolute rates were seen in the group aged 10 to 14 years. The frequency of use of antipsychotics among males was about twice that of females. Patel et al 3 subsequently examined these results by evaluating similar data in additional Medicaid programs, and one managed care organization for the period between 1996 and 2001. This study 3 demonstrated increases in prescription rates over time, with boys having higher rates than girls and increased use with age, peaking in 3 of these 4 populations in the group aged 10 to 14 years. Consistent results were also found using data from an expanded Medicare program in Tennessee, called TennCare. 26 This study 26 While the US studies cited above document trends in SGA use, they derive from specific eligible populations and cannot be used to estimate general population rates. In the United States, the NAMCS and the National Hospital Ambulatory Medical Care Survey, collected representative data through sampling procedures based on data collected from physicians, health care sites, or their records. Cooper et al 28 examined these data for the group aged 2 to 18 years between 1995 and 2002. The mean age at prescription of an antipsychotic was 12.9 years, and two-thirds of recipients were male. This study 28 estimated the overall rate of antipsychotic prescriptions to be 39.4 per 1000 per 2-year interval. The most common indications were ADHD and (or) CD (29%), and the second most common indicator was mood disorder (23.6%). Using census data, population rates were calculated both for the groups aged 2 to 12 and 13 to 18 years; in each case, the prescription rate increased about 5-fold between 1995/96 and 2001/02, leading to rates of 26.9 and 63.8 per 1000 in these 2 groups, respectively, by 2001/02. Similar trends, but lower rates, were reported by Olfson et al 2 in an analysis of NAMCS data. These authors estimated that the annual rate of physician visits that included an antipsychotic prescription was 1341 per 100 000 in the period between 2000 and 2002. Olfson et al 2 reported that by 2001/02, 92.3% of antipsychotic prescriptions from visits involving an antipsychotic prescription were for an SGA, contrasting with persistence of use of FGAs in some of the European studies. Among youth mental health visits in which an antipsychotic was prescribed, DBDs (37.8%), mood disorders (31.8%), pervasive developmental disorders or mental retardation (17.3%), or psychotic disorders (14.2%) were the most frequent diagnoses.
Canada
Three Canadian studies were identified. Two of these used the Manitoba Population Health Research Data Repository, 17, 29 one of which focused on the child and adolescent age group. 17 The 2008 study did not specifically focus on children and adolescents, but did report age-specific rates for the group aged 0 to 18 years. Estimates were found to increase with time (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) , and although the rates for FGAs began to decline in 1997, about 20% of antipsychotic prescriptions in 2006 were for FGAs. In the group 0 to 18 years in 2006, the male rate of antipsychotic use was 8.8 per 1000, whereas it was 3.5 per 1000 for females. A more recent paper, 17 also using the Manitoba Repository, reported the rate of use of antipsychotics in the group aged 0 to 18 years to increase from 1.9 per 1000 in 1999 to 7.4 per 1000 in 2008. Consistent with the international literature, the most common medication was risperidone, the male-to-female ratio was about 2:1 across the entire time interval, and the most common diagnoses were ADHD and CD. These estimates seem fairly close to those reported in the Netherlands 21 and from the population-based study in France, 20 and are lower than those reported by Cooper et al 28 using US data. Also, whereas in the US prescriptions for FGAs appear to have been rare as far back as the late 1990s, the number of prescriptions for these agents resembled that for SGAs in Manitoba in 1999, although the use of FGAs declined after that. In 2008, the proportion of prescriptions written by GPs in Manitoba was 73%. 17 The third study, by Pringsheim et al, 30 used IMS Health data (Canadian Disease and Therapeutic Index) to estimate the number of prescription recommendations for antipsychotics in the group aged 17 years and younger. Increases both for SGAs and FGAs were observed, but increases were much more rapid for SGAs. The most common reasons for SGA recommendations were ADHD (17%), mood disorder (16%), CD (14%), and psychotic disorder (13%). In distinction, the most common reasons for FGAs were a tic disorder (30%) followed by a psychotic disorder (28%). While this study 30 did not report population rates, it was able to document relative change during a 5-year time interval: a 114% increase. The vast majority of the recommendations were for SGAs (95%), and among these risperidone was the most common medication. The recommendations were made mostly (62%) by psychiatrists, which is an interesting observation considering that 2 of the lower-end estimates in the literature derive from GP databases. 18, 22 These estimates differ from the Manitoba studies in that a larger proportion of recommendations were from psychiatrists, and FGAs did not decline dramatically over time, as was reported in Manitoba.
Conclusions
This review uncovered large differences between studies and across countries in which these studies were conducted. However, certain commonalities were also identified. Almost all of the studies reported increases in antipsychotic use, and the use of SGAs in particular. The findings reported by European and US studies are divergent in several respects. One difference is the near disappearance of FGA prescriptions in the United States. In Europe, FGAs continue to be used. The most recent Canadian data from the Pringsheim et al study 30 puts Canada closer to the US pattern in this respect, with 95% of recommendations being for SGAs and a similar picture was reported in Manitoba. 17 Most studies internationally have identified risperidone as the most widely used SGA in childhood and adolescence. Other commonalities include the higher rates of use seen in boys and high rates of use in the group aged 7 years and older, compared with the group aged 0 to 6 years.
Whereas increasing use of antipsychotics, and SGAs in particular, has been widely reported, several studies from this literature indicate that the increase in prevalence is not due exclusively to an increased frequency of new use, but also to a longer duration of use. This emphasizes the importance of safety monitoring. 31 Consistent with this, an Icelandic study reported increasing prevalence between 2003 and 2007, with no apparent change in incidence of antipsychotic use in the population aged 0 to 17 years. 23 The conditions driving the increased use appear most often to be ADHD, conduct and behavioural disturbances, and, to a lesser extent, mood disorders. However, the greater prominence of SGA prescriptions for mood disorders in some of the US studies and the Pringsheim et al study 30 do not align with the Manitoba data, which placed the use of SGAs for mood disorders far below that of ADHD and CD. 17 The frequency of use of antipsychotics in children and adolescents in Canada appears to be lower than that of the United States, more closely resembling estimates from
